MyPharmacy+

Rerifer-CT Chewable Tablet Tangy Mango

Manufactured By Ind Blues Pharma

Salt Synonyms

Rs. 56.05

MRP 59.00

(5% OFF)

Includes all taxes

Package SIZE

strip of 10 Chewable Tablets

Price may vary depending on the product batch*

100% Authentic
Products

Free
Shipping*

Products
Return Policy

Information about Rerifer-CT Chewable Tablet Tangy Mango

Uses / Indications:

Use as directed on the label or as advised by your healthcare provider.

Introduction:

Rerifer-CT Chewable Tablet Tangy Mango can help deal with blood loss and deficiencies. It can be effective in dealing with anaemia. Moreover it can help deal with weakness and fatigue due to blood loss.

How to use:

This tablet may help in the formation of red blood cells|It can also boost the production of haemoglobin|It can help in the healthy formation of new cells|This tablet may support the proper functioning of the body

Description:

Effective in dealing with low levels of iron|Helps in dealing with anaemia|It may help in the proper supply of oxygen in the body|Supports general health and well-being

Benefits:

Safety Advise:

Read the label carefully before use|Do not exceed the recommended dosage|Store in a cool and dry place away from direct sunlight|Keep out of reach of children

Rerifer-CT Chewable Tablet Tangy Mango

Manufactured By Ind Blues Pharma

Salt Synonyms

Rs. 56.05

MRP 59.00

Includes all taxes

Package SIZE

Available Substitutes

1-CC Oral Suspension Sugar Free

Azure Pharmaceuticals

1 Tree Co Q 10 Veg Capsule

Saisir Global Technologies Pvt Ltd

1 Tree Omega 3 6 9 Veg Capsule

Saisir Global Technologies Pvt Ltd

1 Tree Sleep Tight Oral Spray Strawberry

Saisir Global Technologies Pvt Ltd

10 AM Vegetable Capsule

Kachhela Medex Pvt Ltd

Uses / Indications:

Introduction:

How to use:

Description:

Benefits:

Safety Advise:

If you miss a dose:

Fact Box:

Primary Use:

Common Side Effects:

Alcohol Interaction:

Pregnancy Interaction:

Lactation Interaction:

Driving Interaction:

Kidney Interaction:

Liver Interaction:

Q&A: